M. Fevzi Özkaynak

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Children’s Oncology Group (COG) ANBL0032.”.

Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Children’s Oncology Group (COG) ANBL0032.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10523

N/A

0DataRank · unranked

0 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Wendy B. London, Sheena C. Tenney +11 more

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3909

N/A

0DataRank · unranked

216 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan +14 more

Data from Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

(2023)10.1158/1078-0432.c.6531294

N/A

0DataRank · unranked

0 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan +14 more

Data from Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

(2023)10.1158/1078-0432.c.6531294.v1

N/A

0DataRank · unranked

0 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan +14 more

Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma

Molecular Therapy Oncology(2024)10.1016/j.omton.2024.200927

N/A

0DataRank · unranked

10 citations

Meijuan Tian, Uksha Saini, Jessica Ayala-Cuesta, Kayleigh Klose, Alyssa S. Mendelowitz +8 more

Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 in vitro and in vivo in NB xenografts

Molecular Therapy Oncology(2024)10.1016/j.omton.2024.200820

N/A

0DataRank · unranked

5 citations

Gaurav Nayyar, Meijuan Tian, Dean A. Lee, M. Fevzi Özkaynak, Jessica Ayala-Cuesta +11 more